| Date | Title | Description |
| 10.01.2022 | AcelRx Pharmaceuticals Announces the Closing of its Acquisition of Lowell Therapeutics | HAYWARD, Calif., Jan. 10, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings... |
| 15.11.2021 | AcelRx Announces $14 Million Registered Direct Common Stock and Warrant Offering | HAYWARD, Calif., Nov. 15, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised... |
| 16.08.2021 | AcelRx Pharmaceuticals Reports Second Quarter 2021 Financial Results | |
| 17.06.2021 | ACELRX PHARMACEUTICALS, INC.
AcelRx Pharmaceuticals : Announces Agreement with FDA Addressing the Warning Letter Received for DSUVIA® Promotional Materials | HAYWARD, Calif., June 17, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervise... |
| 17.06.2021 | AcelRx Announces Agreement with FDA Addressing the Warning Letter Received for DSUVIA® Promotional Materials | |
| 20.05.2021 | ACELRX PHARMACEUTICALS, INC.
AcelRx Pharmaceuticals : Announces an Investigator-Initiated Study of DSUVIA® in the Emergency Department for Patients with Sickle Cell Disease | HAYWARD, Calif., May 20, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised... |
| 20.05.2021 | AcelRx Announces an Investigator-Initiated Study of DSUVIA® in the Emergency Department for Patients with Sickle Cell Disease | |
| 17.05.2021 | AcelRx Pharmaceuticals Reports First Quarter 2021 Financial Results | |
| 13.05.2021 | Study of DSUVIA® Showing Significant Reduction in Postoperative Opioids and Better OBAS Scores Compared to Control Group to be Presented at the American Society of Regional Anesthesia (ASRA) Annual Me... | |
| 06.05.2021 | AcelRx Announces an Investigator-Initiated Study of DSUVIA® for Use in Same-Day Total Joint Replacement | |
| 06.05.2021 | ACELRX PHARMACEUTICALS, INC.
AcelRx Pharmaceuticals : Announces an Investigator-Initiated Study of DSUVIA® for Use in Same-Day Total Joint Replacement | HAYWARD, Calif., May 6, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised ... |
| 08.04.2021 | AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Taking Buprenorphine Who Require a Surgical Procedure | |
| 08.04.2021 | ACELRX PHARMACEUTICALS, INC.
AcelRx Pharmaceuticals : Announces an Investigator-Initiated Study of DSUVIA® in Patients Taking Buprenorphine Who Require a Surgical Procedure | REDWOOD CITY, Calif., April 8, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare ins... |
| 31.03.2021 | AcelRx Pharmaceuticals Announces Appointment of Marina Bozilenko to the Board of Directors | |
| 25.03.2021 | AcelRx Pharmaceuticals Announces Clinical Data Reporting High Ratings for Healthcare Professional and Patient Satisfaction Following Use of DSUVIA® for Acute Pain in Hospital Settings | |
| 22.03.2021 | AcelRx Announces Presentation and Fireside Chat at the Benzinga Biotech Small Cap Conference | |
| 15.03.2021 | AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results | |
| 17.02.2021 | AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Undergoing Plastic Surgery Procedures | |
| 20.01.2021 | AcelRx Announces Pricing of $27.5 Million Public Offering of Common Stock | |
| 19.01.2021 | AcelRx Announces Underwritten Public Offering of Common Stock | |
| 19.01.2021 | AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Cardiac Surgery Enhanced Recovery Regimen | |
| 14.01.2021 | AcelRx Announces Year-End 2020 Metrics and Review of 2020 Achievements | |
| 10.12.2020 | AcelRx Announces $10 Million Registered Direct Common Stock Offering | |
| 10.12.2020 | AcelRx Pharmaceuticals Announces Publication of Clinical Data on Decreased Postoperative Opioid Requirements and Enhanced Postanesthesia Recovery Following Perioperative Use of DSUVIA® | |
| 04.12.2020 | AcelRx Pharmaceuticals Announces Partnership with the National Rural Health Association | |
| 18.11.2020 | AcelRx Pharmaceuticals Announces Commentary in Practical Pain Management on Previously Published Clinical Data on Preoperative Administration of DSUVIA® | |
| 16.03.2020 | AcelRx Pharmaceuticals to Acquire Tetraphase Pharmaceuticals | AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a Redwood City-based specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, is to acquire Tetraphas... |
| 30.09.2015 | Daily funding roundup - September 30, 2015 | Avant scored $325M; NewStore raised $38M; PerfectServe landed $21M
Molio, Inc., a Salt Lake City-based creative and media agency focused on building brands through YouTube, raised a $1 million credit facility. Square 1 Bank provided the fin... |
| 25.09.2012 | Improving patient safety has to involve stopping errors with infusion pumps for post-op pain | A subset of these pumps is used to deliver opium-like painkillers. These devices, referred to as intravenous patient-controlled analgesia (IV PCA), have been crucial to inpatient care. They allow patients themselves to control the delivery ... |
| 04.04.2011 | Tranzyme Pharma’s public offering raises $48M but IPO has little bounce | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| - | AcelRx Pharmaceuticals | “Home | AcelRx Pharmaceuticals, Inc.” |
| - | Improving patient safety has to involve stopping errors with infusion pumps for post-op pain | The recently released Consumer Reports’ Hospital Ratings of more than 1,000 U.S. hospitals highlighted the need to reduce hospital-caused patient harm. On a safety scale with 100 being the highest, only 158 hospitals received a score of hig... |
| - | Tranzyme Pharma’s public offering raises $48M but IPO has little bounce | Tranzyme Pharma (NASDAQ:TZYM) likely had hopes for an opening bounce on the day the drug development company went public, but that ball fell flat.
The Research Triangle Park, North Carolina company’s stock price closed at $4 per share, the ... |
